Disease detection, access to care and remote patient monitoring are just a few areas in which AI is expected to aid rheumatology, but there will still be room for the human touch.
Stay Current on Coding Guidelines with ACR Lunch-and-Learns
Available topics include CPT telemedicine code sets, G2211 coding updates, evolving HIPAA guidelines, evaluation and management (E/M) coding and billing strategies.
Rheumatologist Elected to Key AMA Committee That Helps CMS Set Medicare Reimbursements
Luke Barré, MD, MPH, RhMSUS, has been elected to the American Medical Association’s Relative Value Update Committee. He is the second rheumatologist to hold the seat in recent years and will ensure representation of the specialty during valuation of physician services.
ACR Comments on Proposed Medicare Advantage Changes
In response to proposed changes to the Medicare Advantage and prescription drug programs for contract year 2026, the ACR submitted comments on the provisions related to the Inflation Reduction Act, prior authorization and the influence that pharmacy benefit managers have on the placement of biosimilars on formularies.
The Burden Imposed by Prior Authorization Requirements
‘Prior authorizations are the bane of our existence as rheumatologists,’ says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS. ‘How bad is it, how can we manage them, and how is the ACR helping? Read on in this month’s Editor’s Pick.’ Healthcare providers consider prior authorization (PA) a significant burden, but to different degrees…
Precision Medicine on a Population Level
Guest columnists Dr. Daniel Solomon & Dr. Andrew Concoff discuss the potential of technology, such as mobile health apps, to enhance remote care & improve access for underserved patients.
2024 Federal Legislative Recap
Although many rheumatology priorities were cut from big funding bills in the 118th Congress, some policy victories and signals of progress set the stage for the new year
Precision Medicine on a Population Level: Can Digital Health Technology Improve Access to Rheumatologic Care?
Over our 25 years as rheumatologists, care has advanced greatly. We each completed our rheumatology training in the late 1990s when both infliximab and etanercept first arrived on the U.S. market, ushering in the era of biologics in rheumatology. Since this time, our greater understanding of the immunologic basis of many rheumatic diseases has translated…
Hit the Ground Running with New Insurance Subcommittee Chair Michael Feely, MD
Dr. Feely discusses his previous work with the College, his current work as a practicing rheumatologist and how he will lead continued advances on the insurance front.
Rheuminations: Imagine a Better World for Clinicians & Our Patients
The world didn’t end on Jan. 1, 2000. The Y2K bug didn’t crash airplanes and liquidate bank assets. We were, overall, hopeful for the future—a new millennium full of futuristic visions of a techno-utopia. Fast forward a quarter of a century and we now live in that technologically advanced age that once seemed so far…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 176
- Next Page »